Nice | Idelalisib for treating chronic lymphocytic leukaemia

15th February 2016 by Louise Hudman

Nice | Idelalisib for treating chronic lymphocytic leukaemia

This is a new guideline from NICE on idelalisib use in chronic lymphocytic leukaemia. Idelalisib is likely to be secondary care prescribed, but I felt it was worthwhile knowing about as it is a new type of drug and we will probably see patients on it.

Idelalisib is an oral drug and will be used in combination with rituximab infusions. It is a ‘first-in-class’ drug which inhibits enzymes involved in cell proliferation, death and migration.

Side-effects

Among other side-effects, it can raise transaminases, triglycerides and can cause neutropenia.

Read for free

Sign up to access everything.

Free trial

Login

Already a member? Login to view this content.

Login

"LocumDeck is self-explanatory and having never made/sent an invoice before it's made my life a lot easier, and made me feel reassured I hadn’t forgotten anything important.

I’ve recommended it to my colleague/friend who is also starting out as a GP locum."

Dr Christine Vickery

Dr Christine Vickery

See the full list of features within our NASGP membership plans

Membership